Scancell Holdings plc (LON:SCLP – Get Free Report) traded up 7.6% on Tuesday . The stock traded as high as GBX 19.50 and last traded at GBX 18.72. 3,932,149 shares changed hands during trading, an increase of 130% from the average session volume of 1,708,538 shares. The stock had previously closed at GBX 17.40.
Scancell Price Performance
The firm has a market cap of £196.66 million, a PE ratio of -34.45 and a beta of 0.57. The firm has a fifty day simple moving average of GBX 12.93 and a two-hundred day simple moving average of GBX 11.73. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
See Also
- Five stocks we like better than Scancell
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
